Comment: Compulsory Licensing of Patented Pharmaceutical Inventions: Evaluating the Options
Identifieur interne : 001245 ( Main/Exploration ); précédent : 001244; suivant : 001246Comment: Compulsory Licensing of Patented Pharmaceutical Inventions: Evaluating the Options
Auteurs : Jerome H. ReichmanSource :
- The Journal of Law, Medicine & Ethics [ 1073-1105 ] ; 2009-06.
Abstract
In this Comment, the author traces the relevant legislative history pertaining to compulsory licensing of patented pharmaceuticals from the TRIPS Agreement of 1994 to the 2003 waiver to, and later proposed amendment of, article 31, which enables poor countries to obtain needed medicines from other countries that possess manufacturing capacity. The Comment then evaluates recent, controversial uses of the relevant legislative machinery as viewed from different critical perspectives. The Comment shows how developing countries seeking access to essential medicines can collaborate in ways that would avoid undermining incentives to innovation and other social costs attributed to compulsory licensing. It ends by defending the legality of recent measures taken to promote public health in developing countries, and by reminding developed countries that unilateral retaliation against such measures is demonstratably illegal under WTO foundational law and jurisprudence.
Url:
- https://api.istex.fr/document/57FB881C0C2A5AC84843A6E35123735F991D2E09/fulltext/pdf
- http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2893582
DOI: 10.1111/j.1748-720X.2009.00369.x
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: 000F21
- to stream Istex, to step Curation: 000F12
- to stream Istex, to step Checkpoint: 000D54
- to stream Pmc, to step Corpus: 000282
- to stream Pmc, to step Curation: 000282
- to stream Pmc, to step Checkpoint: 000410
- to stream Ncbi, to step Merge: 000054
- to stream Ncbi, to step Curation: 000054
- to stream Ncbi, to step Checkpoint: 000054
- to stream Main, to step Merge: 001247
- to stream Main, to step Curation: 001245
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Comment: Compulsory Licensing of Patented Pharmaceutical Inventions: Evaluating the Options</title><author><name sortKey="Reichman, Jerome H" sort="Reichman, Jerome H" uniqKey="Reichman J" first="Jerome H." last="Reichman">Jerome H. Reichman</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:57FB881C0C2A5AC84843A6E35123735F991D2E09</idno><date when="2009" year="2009">2009</date><idno type="doi">10.1111/j.1748-720X.2009.00369.x</idno><idno type="url">https://api.istex.fr/document/57FB881C0C2A5AC84843A6E35123735F991D2E09/fulltext/pdf</idno><idno type="wicri:Area/Istex/Corpus">000F21</idno><idno type="wicri:Area/Istex/Curation">000F12</idno><idno type="wicri:Area/Istex/Checkpoint">000D54</idno><idno type="wicri:doubleKey">1073-1105:2009:Reichman J:comment:compulsory:licensing</idno><idno type="wicri:source">PMC</idno><idno type="url">http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2893582</idno><idno type="RBID">PMC:2893582</idno><idno type="wicri:Area/Pmc/Corpus">000282</idno><idno type="wicri:Area/Pmc/Curation">000282</idno><idno type="wicri:Area/Pmc/Checkpoint">000410</idno><idno type="wicri:Area/Ncbi/Merge">000054</idno><idno type="wicri:Area/Ncbi/Curation">000054</idno><idno type="wicri:Area/Ncbi/Checkpoint">000054</idno><idno type="wicri:doubleKey">1073-1105:2009:Reichman J:compulsory:licensing:of</idno><idno type="wicri:Area/Main/Merge">001247</idno><idno type="wicri:Area/Main/Curation">001245</idno><idno type="wicri:Area/Main/Exploration">001245</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Comment: Compulsory Licensing of Patented Pharmaceutical Inventions: Evaluating the Options</title><author><name sortKey="Reichman, Jerome H" sort="Reichman, Jerome H" uniqKey="Reichman J" first="Jerome H." last="Reichman">Jerome H. Reichman</name><affiliation><wicri:noCountry code="subField">N.C.</wicri:noCountry></affiliation></author></analytic><monogr></monogr><series><title level="j">The Journal of Law, Medicine & Ethics</title><idno type="ISSN">1073-1105</idno><idno type="eISSN">1748-720X</idno><imprint><publisher>Blackwell Publishing Ltd</publisher><pubPlace>Oxford, UK</pubPlace><date type="published" when="2009-06">2009-06</date><biblScope unit="volume">37</biblScope><biblScope unit="issue">2</biblScope><biblScope unit="page" from="247">247</biblScope><biblScope unit="page" to="263">263</biblScope></imprint><idno type="ISSN">1073-1105</idno></series><idno type="istex">57FB881C0C2A5AC84843A6E35123735F991D2E09</idno><idno type="DOI">10.1111/j.1748-720X.2009.00369.x</idno><idno type="ArticleID">JLME369</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">1073-1105</idno></seriesStmt></fileDesc><profileDesc><textClass></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">In this Comment, the author traces the relevant legislative history pertaining to compulsory licensing of patented pharmaceuticals from the TRIPS Agreement of 1994 to the 2003 waiver to, and later proposed amendment of, article 31, which enables poor countries to obtain needed medicines from other countries that possess manufacturing capacity. The Comment then evaluates recent, controversial uses of the relevant legislative machinery as viewed from different critical perspectives. The Comment shows how developing countries seeking access to essential medicines can collaborate in ways that would avoid undermining incentives to innovation and other social costs attributed to compulsory licensing. It ends by defending the legality of recent measures taken to promote public health in developing countries, and by reminding developed countries that unilateral retaliation against such measures is demonstratably illegal under WTO foundational law and jurisprudence.</div></front></TEI><affiliations><list></list><tree><noCountry><name sortKey="Reichman, Jerome H" sort="Reichman, Jerome H" uniqKey="Reichman J" first="Jerome H." last="Reichman">Jerome H. Reichman</name></noCountry></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Belgique/explor/OpenAccessBelV2/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001245 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 001245 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Belgique
|area= OpenAccessBelV2
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:57FB881C0C2A5AC84843A6E35123735F991D2E09
|texte= Comment: Compulsory Licensing of Patented Pharmaceutical Inventions: Evaluating the Options
}}
| This area was generated with Dilib version V0.6.25. |  |